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Report on the annual statistical survey of the Japanese Society 145,689 in Europe at the close of 1994 [1], against 193,995
for Dialysis Therapy in 1996. in the United States at the end of 1995 [2]. Thus, a
Background. Nearly 170,000 patients were treated by main- significant number of patients are treated by mainte-tenance renal replacement therapy (RRT) in Japan in 1996.
nance RRT in Japan, as well as in Europe and in theThe current status of Japanese patients on RRT might, in some
United States.way, be suggestive for patients on RRT in other countries.
Methods. The Japanese Society for Dialysis Therapy con- Thanks to an improved prognosis, there is a worldwide
ducts a questionnaire survey of virtually every dialysis facility increase in the number of patients on long-term treat-
in Japan at the end of each year. Here we present the results ment. Thus, the various complications accompanyingof our survey of patients undergoing RRT as of the end of
long-term treatment [3, 4] may pose one of the major1996, as well as five-year trends (1992–1996) in some of the
problems for maintenance hemodialysis (HD) therapy.data.
Results. The response rate was 99.8%. At the end of 1996, Comparing the duration of HD therapy in Europe, which
there were 167,192 patients on maintenance RRT in Japan is reported elsewhere [5], versus that in Japan, the mean
(1,328 persons per million population). The numbers of pa- length on HD seems to be longer in Japan than in Eu-tients on maintenance RRT continued to increase during the
rope. This may be because very few end-stage renalfive-year period. The gross mortality rate for that period ranged
failure patients receive kidney transplants in Japan com-from 9.4% to 9.7%. Cuprammonium rayon was the most com-
monly used material (24.0%) for dialyzer membranes, followed pared with Europe. For the same reason, the mean length
by cellulose triacetate (18.7%). Approximately 5.0% of hemo- on HD also may be longer in Japan than in the United
dialysis (HD) patients had a prior history of surgical release States. Only 0.2% of maintenance HD patients receivedof carpal tunnel. The longer the years on HD therapy, the
kidney transplants in Japan in 1996 according to thisgreater the proportion of patients with a history of such an
survey’s results (data not shown), whereas 4.4% receivedoperation. The predialysis plasma b2-microglobulin concentra-
tion was highest in patients aged 30 to 45 years and declined transplants in Europe in 1994 [1] and 16.5% received
slightly after the age of 45. There was no significant difference transplants in the United States in 1995 [2]. Hence, it is
in the HbA1c level between continuous ambulatory peritoneal safe to say that the Japanese HD patient faces moredialysis and HD patients, both in whom diabetes was the dis-
problems surrounding long-term HD.ease causing renal failure. Moreover, among HD patients with
The current status of Japanese patients on RRT might,diabetes, there was a clear tendency for the HbA1c level to be
higher when the normalized protein catabolic rate was higher. in some way, be suggestive for patients on RRT in other
Conclusion. This report summarizes the latest results of the countries. We therefore report the results of our survey
survey on Japanese patients on RRT. of patients undergoing RRT as of the end of 1996 and,
at the same time, present five-year trends (1992–1996)
for some of the data.
The number of patients on maintenance renal replace-
ment therapy (RRT) in Japan at the end of 1996 was
METHODSapproximately 167,000, while such patients numbered
Survey methods
The Patient Registration Committee of the JapaneseKey words: dialysis in Japan, renal replacement therapy, amyloidosis,
CAPD, carpal tunnel syndrome, erythropoietin, glycohemoglobin A1c. Society for Dialysis Therapy annually mails a survey at
the end of November to the heads of all of the dialysisReceived for publication May 6, 1998
facilities on record at the society headquarters at theand in revised form September 18, 1998
Accepted for publication September 21, 1998 time. The heads of the various facilities surveyed are
requested to return their survey replies by the end of 1999 by the International Society of Nephrology
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January of the following year to the above-mentioned with different time lengths on RRT, an analysis of covari-
ance was performed with the parameter to be comparedcommittee. If the committee fails to receive the survey
replies from a given institution, it sends out an inquiry as the dependent variable and several related case mix
and/or laboratory variables as the independent variables.to that effect to the head of that facility. If the reply is
still not received, the committee faxes and phones the By adjusting with several related case mix and/or labora-
tory variables (that is, independent variables), the leasthead of the facility to request his or her cooperation. It
is only after these efforts have failed to evoke a reply square mean of the parameter to be compared (depen-
dent variables) was computed for each of the respectiveby April 30 that the facility in question is considered to
be a nonresponder. The number of facilities surveyed male and female patient groups, diabetes and nondiabe-
tes groups, different age groups, or groups of differenthas increased yearly since 1966, the inception of the
yearly survey, and as of 1996, the number reached 2,968 time lengths on RRT. Then the least square mean of the
parameter was compared between the male and femalefacilities.
With the 1994 year-end survey, facilities wishing for groups, between diabetes and nondiabetes groups,
among different age groups, or among groups of differentthe survey form on floppy diskette instead of the usual
hard-copy forms were sent the diskette. As of the 1996 time lengths on RRT.
For the analysis of covariance, the SAS software foryear-end survey, 681 facilities chose the floppy diskette to
complete the questionnaire survey. The floppy diskette statistical analyses was used (SAS/STAT Users’ Guide
Release 6.03 Edition; Tokyo, Japan). The t-test by Fish-survey forms allowed more information to be included
than in the hard-copy forms, and thus, more survey items er’s least significant difference method was employed
for comparison of the least square means obtained.could be incorporated. Thus, the floppy disk survey ver-
sion included more items such as recombinant human Data other than the results of analysis of covariance
are presented as means 6 sd, whereas the results oferythropoietin dose administered, cardiothoracic ratio,
and systolic and diastolic blood pressures. analyses of covariance are expressed as least square
means 6 se. A P value of less than 0.05 was regarded
Survey items as statistically significant.
The survey covered the following items: (a) the status
of facilities (that is, the numbers of personnel, HD ma-
RESULTS
chines, beds, and patients treated at a given facility);
Dialysis facility status(b) the case mix and laboratory data of each patient
beginning RRT at the facility between January 1 and According to the survey results on the “Current Status
of Dialysis Facilities,” private clinics accounted for 38.0%,December 31 of the year surveyed, as well as relevant
information on important events occurring in patients whereas 33.4%, 24.7%, and 4.0% accounted for private,
public, and university hospitals, respectively. On the otherduring the year surveyed (death, change in the form of
therapy, kidney transplantation); (c) the same data of (b) hand, approximately 39.3% of the overall patients were
treated in private clinics, 37.6% in private hospitals,with regards to all patients who had been on maintenance
RRT at the facility concerned as of December 31 of the 20.9% in public hospitals and 2.3% in university hospi-
tals. In Japan, a private clinic is a medical facility fundedyear surveyed.
by private investment and having 19 or fewer beds. A
Response rate private hospital is also funded with private investment
but has 20 or more beds. A public hospital is publiclyCompleted survey forms were obtained from 2,961
(99.8%) of the 2,968 institutions surveyed by the 1996 financed and designated. Usually, a public hospital is a
general hospital, not a special facility for dialysis treat-mailed-out survey questionnaire. Of the responder facili-
ties, however, 123 of the surveyed facilities (4.2%) re- ment; an HD center is rather one department or part of
a general hospital.plied only to inquiries on the status of dialysis facilities.
In the five-year period leading up to 1996, over 99% of Number of patients beginning RRT. Hemodialysis
(HD), hemodiafiltration (HDF), hemofiltration (HF),the facilities responded to the “Current Status of Dialysis
Facilities” inquiry, whereas only approximately 95% re- hemodiabsorption, continuous ambulatory peritoneal di-
alysis (CAPD), and intermittent peritoneal dialysis (IPD)sponded to the portion of the questionnaire dealing with
individual patient case mix, laboratory data, and out- were defined as RRT. In this report, however, kidney
transplantation is not included in the RRT category.come.
Approximately 28,409 patients began RRT in 1996.
Data analysis As shown in Table 1, the five-year period up to 1996
showed an increasing number of patients starting RRT.To compare a certain parameter between male and
female patient groups, between those with and without Total number of patients on maintenance RRT. There
was a total of 167,192 patients on maintenance RRT atdiabetes, among different age groups, or among groups
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Table 1. Survey results on the status of dialysis facilities in Japan
1992 1993 1994 1995 1996
Number of facilities 2,520 2,629 2,752 2,866 2,961
Number of dialysis machines 49,650 53,262 58,561 59,715 63,742
Number of patients on dialysis therapy 123,926 134,298 143,709 154,413 167,192
Number of patients beginning dialysis therapy 22,475 23,874 24,296 26,398 28,409
Number of patient deaths 11,621 12,143 13,187 14,406 15,174
Prevalence/million population 995.8 1,076.4 1,149.4 1,229.7 1,328.4
Gross mortality rate % 9.7 9.4 9.5 9.7 9.4
the end of 1996. On the basis of this number of patients, As shown in Table 2, over the five-year period, the
overall number of patients beginning RRT rose, whereasthere were 1,328 patients on such therapy per million
Japanese population as of the end of 1996. As indicated the proportion of patients treated with respective treat-
ment modality remained virtually the same.in Table 1, the number of patients on maintenance RRT
has been rising at the respective year end, and accord- Patients beginning extracorporeal hemopurification.
Among the 28,234 patients beginning RRT in 1996, asingly, the number of patients per million population is
also on the increase each year. of the end of that year, 26,548 patients were being treated
by HD, HDF, HF, or hemodiabsorption. These patientsNumber of patient deaths (total among those on HD,
HDF, HF, hemodiabsorption, CAPD, and IPD). There coming on HD, HDF, HF, or hemodiabsorption were
grouped as “extracorporeal hemopurification patients.”were 15,174 deaths in 1996 among the patients on mainte-
nance RRT. Table 1 indicates a yearly increase in the Again, because 98.6% of such patients received HD,
extracorporeal hemopurification virtually meant HD.number of deaths, but they are fewer than the number
of patients beginning RRT yearly. Of the patients beginning extracorporeal hemopurifi-
cation between January 1 and December 31, 1996, thereAnnual gross mortality rates. The gross mortality rate
for a given year is the ratio of the number of patient were 16,281 males and 10,223 females. In 44 patients,
sex was not specified in the survey replies. Males ac-deaths relative to the number of patients for the year.
In 1996, the gross mortality rate was 9.4%. As indicated counted for 61.4%, whereas females accounted for 38.6%.
The mean age was 62.4 6 13.7 years for patients at thein Table 1, the gross mortality rates ranged from 9.4%
to 9.7% during the five-year period. end of 1996 who had begun extracorporeal hemopurifi-
cation therapy between January 1 and December 31 of
Survey results on current status of individual patients that year. Table 2 shows the gradually increasing trend
in the mean age among the patients starting such therapy.Patients beginning RRT. The number of patients be-
ginning RRT may also be available from the survey re- The most frequent cause of the chronic renal failure
in patients beginning extracorporeal hemopurificationsults on the current status of individual patients. The
number starting RRT in 1996 was 28,234 patients, ac- therapy in 1996 was found to be chronic glomerulonephri-
tis (38.2%), followed by diabetic nephropathy (33.8%),cording to the survey results on the current status of
individual patients. This figure was lower than the num- nephrosclerosis (6.5%), polycystic kidney (2.6%), and
lupus nephritis (1.2%).ber cited as beginning RRT in the “Status of Dialysis
Facilities” questionnaire for 1996. This difference was As indicated in Table 3, during the five-year period,
the proportion of the patients beginning treatment whosethought to be due to the fact that some institutions failed
to send back replies to the inquiry on the current status kidney disease was glomerulonephritis decreased stead-
ily, but more and more patients whose kidney disease wasof individual patients.
Thus, the number of patients based on the survey diabetic nephropathy were beginning treatment. Also,
chronic pyelonephritis, the fifth most common kidneyresults on the current status of individual patients may
be slightly underestimated, but information on RRT it- disease among new patients on extracorporeal hemopur-
ification therapy up until 1995, displayed a decreasingself may be deemed accurate. According to the results
of the 1996 questionnaire survey dealing with the current trend during the five-year period. As a result, in 1996,
lupus nephritis took over as the fifth most common kid-status of each patient, of the 28,234 patients beginning
RRT, some 92.9% were on HD, 1.0% on HDF, 0.2% ney disease among patients beginning extracorporeal
hemopurification therapy, and chronic pyelonephritison HF, 0.1% on hemodiabsorption, 5.5% on CAPD,
0.1% on IPD, and 0.2% were on unspecified dialysis dropped back to sixth place.
CAPD patients beginning RRT in 1996. Among thetreatment as of December 31, 1996. Only 0.2% of the
patients beginning RRT received a kidney transplanta- patients beginning RRT in 1996, these data were com-
piled on those who were undergoing CAPD treatmenttion in 1996.
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Table 2. Number of patients starting renal replacement therapy in each year
1992 1993 1994 1995 1996
N % N % N % N % N %
Hemodialysis 19,858 92.1 21,754 92.8 22,305 92.7 23,963 92.7 26,179 92.7
Hemodiafiltration 255 1.2 169 0.7 252 1.0 252 1.0 295 1.0
Hemofiltration 63 0.3 44 0.2 35 0.1 26 0.1 56 0.2
Hemodiabsorption 20 0.1 7 0.0 30 0.1 13 0.1 18 0.1
Home hemodialysis 3 0.0 1 0.0 0 0.0 0 0.0 0 0.0
CAPD 1,189 5.5 1,379 5.9 1,374 5.7 1,407 5.4 1,540 5.5
IPD 22 0.1 9 0.0 17 0.1 37 0.1 41 0.1
Unknown/secession 141 0.7 11 0.0 20 0.1 124 0.5 57 0.2
Sub-total 21,551 99.0 23,374 99.7 24,033 99.9 25,822 99.9 28,186 99.8
Cadaver graft 11 0.1 61 0.3 26 0.1 36 0.1 48 0.2
Living graft 1 0.0 5 0.0 0 0.0 0 0.0 0 0.0
Sub-total 12 0.1 66 0.3 26 0.1 36 0.1 48 0.2
Grand total 21,563 100.0 23,440 100.0 24,059 100.0 25,858 100.0 28,234 100.0
Mean age when therapy started 6 sd
Extracorporeal hemopurification 60.3 6 14.1 60.8614.0 61.3 613.9 61.9 613.8 62.4 613.7
CAPD 52.8 6 16.9 52.7616.2 54.1 616.4 53.3 616.9 54.3 617.2
N is the number of patients.
Table 3. Number of extracorporeal hemopurification patients starting renal replacement therapy in the year surveyed
according to different kidney diseases
1992 1993 1994 1995 1996
Kidney disease N % N % N % N % N %
Missing 1,244 6.2 1,451 6.6 1,381 6.1 1,277 5.3 1,038 3.9
Chronic glomerulonephritis 8,400 41.6 8,900 40.5 9,002 39.8 9,358 38.6 10,150 38.2
Chronic pyelonephritis 310 1.5 252 1.1 314 1.4 291 1.2 294 1.1
Rapidly progressive glomerulonephritis 142 0.7 178 0.8 177 0.8 194 0.8 216 0.8
Gestational toxicosis 83 0.4 90 0.4 82 0.4 79 0.3 81 0.3
Nephritis that is impossible to categorize 97 0.5 116 0.5 123 0.5 88 0.4 92 0.3
Polycystic kidney disease 566 2.8 591 2.7 579 2.6 589 2.4 678 2.6
Nephrosclerosis 1,185 5.9 1,377 6.3 1,405 6.2 1,539 6.3 1,725 6.5
Malignant hypertension 146 0.7 144 0.7 159 0.7 199 0.8 169 0.6
Diabetic nephropathy 5,849 29.0 6,773 30.8 7,064 31.2 7,944 32.8 8,968 33.8
Systemic lupus erythematosus 264 1.3 258 1.2 265 1.2 271 1.1 325 1.2
Amyloid nephropathy 128 0.6 151 0.7 131 0.6 130 0.5 148 0.6
Gouty nephropathy 139 0.7 111 0.5 113 0.5 155 0.6 109 0.4
Renal failure caused by metabolic disorder 9 0.0 14 0.1 18 0.1 23 0.1 12 0.0
Tuberculosis 48 0.2 47 0.2 39 0.2 58 0.2 56 0.2
Urethral stone 38 0.2 40 0.2 67 0.3 50 0.2 54 0.2
Malignant tumor of kidney or urinary tract 97 0.5 106 0.5 103 0.5 108 0.4 112 0.4
Obstructive urinary tract disease 96 0.5 111 0.5 102 0.5 104 0.4 127 0.5
Myeloma kidney 102 0.5 93 0.4 90 0.4 130 0.5 128 0.5
Renal hypoplasia 32 0.2 28 0.1 42 0.2 36 0.1 25 0.1
Unknown 755 3.7 746 3.4 881 3.9 1,094 4.5 1,340 5.0
Reentry after transplantation 47 0.2 48 0.2 66 0.3 39 0.2 72 0.3
Others 422 2.1 350 1.6 419 1.9 498 2.1 629 2.4
Total 20,199 100.0 21,975 100.0 22,622 100.0 24,254 100.0 26,548 100.0
N is the number of patients.
at the close of 1996. Of the 1,540 patients beginning ning CAPD therapy in 1994 proved to be chronic glomer-
ulonephritis (51.0%), followed by diabetic nephropathyCAPD treatment between January 1 and December 31,
1996, 960 were male, and 575 were female; the sex was (23.1%), nephrosclerosis (5.1%), polycystic kidney
(1.7%), and lupus nephritis (1.6%).not specified for five patients in the survey replies. Male
patients accounted for 62.5%, whereas 37.5% were fe- Table 4 shows that during the five-year period up to
1996, there were no major changes in the proportion ofmale patients. The mean age of patients who began
CAPD treatment in 1996 was 54.3 6 17.2 years. CAPD patients with different kidney disease.
Patients on maintenance RRT. From the survey resultsThe most frequent kidney disease in patients begin-
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Table 4. Number of CAPD patients starting renal replacement therapy in the year surveyed according to different kidney diseases
1992 1993 1994 1995 1996
Kidney disease N % N % N % N % N %
Missing 55 4.6 119 8.6 88 6.4 50 3.6 32 2.1
Chronic glomerulonephritis 637 53.6 766 55.5 711 51.7 786 55.9 786 51.0
Chronic pyelonephritis 24 2.0 14 1.0 11 0.8 17 1.2 14 0.9
Rapidly progressive glomerulonephritis 10 0.8 5 0.4 7 0.5 4 0.3 7 0.5
Gestational toxicosis 8 0.7 9 0.7 6 0.4 8 0.6 9 0.6
Nephritis that is impossible to categorize 7 0.6 12 0.9 9 0.7 13 0.9 16 1.0
Polycystic kidney disease 13 1.1 22 1.6 22 1.6 23 1.6 26 1.7
Nephrosclerosis 72 6.1 73 5.3 67 4.9 86 6.1 79 5.1
Malignant hypertension 8 0.7 11 0.8 8 0.6 9 0.6 11 0.7
Diabetic nephropathy 242 20.4 229 16.6 302 22.0 264 18.8 356 23.1
Lupus nephritis 18 1.5 17 1.2 19 1.4 23 1.6 24 1.6
Amyloid nephropathy 8 0.7 8 0.6 5 0.4 6 0.4 11 0.7
Gouty nephropathy 10 0.8 13 0.9 6 0.4 13 0.9 12 0.8
Renal failure caused by metabolic disorder 3 0.3 2 0.1 2 0.1 6 0.4 4 0.3
Tuberculosis 1 0.1 1 0.1 1 0.1 0 0.0 3 0.2
Urethral stone 4 0.3 4 0.3 4 0.3 1 0.1 3 0.2
Malignant tumor of kidney or urinary tract 4 0.3 1 0.1 3 0.2 0 0.0 1 0.1
Obstructive urinary tract disease 7 0.6 3 0.2 9 0.7 6 0.4 10 0.6
Myeloma kidney 1 0.1 4 0.3 1 0.1 2 0.1 0 0.0
Renal hypoplasia 5 0.4 11 0.8 9 0.7 15 1.1 22 1.4
Unknown 29 2.4 30 2.2 52 3.8 49 3.5 70 4.5
Reentry after transplantation 2 0.2 1 0.1 4 0.3 2 0.1 4 0.3
Others 21 1.8 24 1.7 28 2.0 24 1.7 40 2.6
Total 1,189 100.0 1,379 100.0 1,374 100.0 1,407 100.0 1,540 100.0
N is the number of patients.
Table 5. Number of patients on renal replacement therapy in the year surveyed
1992 1993 1994 1995 1996
N % N % N % N % N %
Hemodialysis 111,923 92.0 121,560 92.4 130,922 91.8 139,925 91.8 150,141 91.6
Hemodiafiltration 2,155 1.8 2,529 1.9 3,485 2.4 3,543 2.3 4,508 2.7
Hemofiltration 165 0.1 145 0.1 121 0.1 127 0.1 125 0.1
Hemodiabsorption 24 0.0 18 0.0 107 0.1 41 0.0 63 0.0
Home hemodialysis 89 0.1 95 0.1 93 0.1 84 0.1 17 0.0
CAPD 5,451 4.5 6,490 4.9 7,196 5.0 7,756 5.1 8,164 5.0
IPD 27 0.0 35 0.0 42 0.0 83 0.1 134 0.1
Unknown/secession 1,821 1.5 620 0.5 660 0.5 814 0.5 808 0.5
Total 121,655 100.0 131,492 100.0 142,626 100.0 152,373 100.0 163,960 100.0
Mean age when therapy started 6SD
Extracorporeal hemopurification 56.2 6 13.3 56.9 6 13.3 57.6 6 13.3 58.3 6 13.2 58.9 6 13.2
CAPD 50.6 6 15.0 51.0 6 15.0 51.3 6 15.0 51.7 6 15.0 52.3 6 15.0
N is the number of patients.
on the individual patient status in 1996, the modalities Patients on maintenance extracorporeal hemopurifi-
cation. Of the 154,854 patients undergoing extracorpo-of therapy given the 163,960 patients at the end of 1996
were as follows: HD (91.6%, including 0.01% of patients real hemopurification treatment at the end of 1996,
91,870 were male, and 62,896 were female. In 88 patients,treated at home), HDF (2.7%), HF (0.1%), hemodiab-
sorption (0.04%), CAPD (5.0%), IPD (0.1%), and un- sex was not specified in the survey replies. Male patients
accounted for 59.4%, whereas 40.6% were female. Thespecified dialysis therapy (0.5%).
As indicated in Table 5, the overall number of patients mean age was 58.9 6 13.2 years. The mean length on
hemopurification was 5.9 6 5.9 years. Overall, 53.6%on maintenance RRT continued to grow during the five-
year period. However, other than a slight decrease in patients were on treatment for less than five years,
whereas 22.9% had been treated for more than 5 butthe number of patients on home HD or a slight increase
in the proportion of patients treated with HDF, no great less than 10 years. In those over 10 years but less than 15
years, 12.4% were on extracorporeal hemopurification,changes were noted in the proportionate use of various
modalities of therapy. with 7.5% for more than 15 but less than 20 years, 3.4%
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for more than 20 but less than 25 years, and 0.3% for and infectious diseases tended to increase during the
five-year period concerned.more than 25 years. As of the end of 1996, the patient
who had been on extracorporeal hemopurification (that
Cumulative survival rate of patients beginning RRT inis, HD) the longest had been treated for 30 years.
or after 1983The causes of chronic renal failure in patients receiving
maintenance extracorporeal hemopurification as of De- Patients on extracorporeal hemopurification. In this
survey, the cumulative survival rates of patients begin-cember 31, 1996, were ranked as follows: chronic glomer-
ulonephritis (53.5%), diabetic nephropathy (21.7%), ning RRT during or after 1983 were computed by the
Cutler-Ederer method. The one-year survival rate wasnephrosclerosis (3.9%), polycystic kidney (3.2%), and
chronic pyelonephritis (1.6%). 0.893. The five-year survival rate was 0.601, and the 10-
year survival rate was 0.388 in the patients on extracorpo-CAPD patients. Among the 8,164 CAPD patients on
record as of the end of 1996, 4,876 were male, and 3,273 real hemopurification. These survival rates were almost
equivalent to those in the 1994 survey.were female. In 15 patients, the gender was not specified
in the survey replies. Male patients accounted for 59.8%, The diseases with the best prognosis and the poorest
prognosis in terms of 10-year survival in this survey werewhereas 40.2% were female. The mean age was 52.3 6
15.0 years as of the end of that year. Like patients on similar with those in the 1994 survey. The diseases with
a more favorable prognosis were gestational toxicosis,other treatment modalities, CAPD patients tended to
show a slight increase in mean age. The patients treated renal hypoplasia, polycystic kidney, and chronic glomer-
ulonephritis in that order. Diseases with the poorestby CAPD at the end of 1996 had been treated for an
average 4.0 6 4.3 years by RRT. Here, “years on RRT” prognosis were myeloma kidney, amyloid nephropathy,
malignant tumor of kidney or urinary tract, metabolicmeant the years a patient had been on any form of RRT,
not the actual number of years on CAPD itself. The disorder, and diabetic nephropathy in the order of less
favorable outlook.duration on any form of RRT in these patients was as
follows: 67.4% for less than 5 years, 22.6% more than 5 CAPD patients. The survival rates for CAPD patients
in this survey were almost the same as those in the 1994but less than 10 years, 6.4% more than 10 but less than
15 years, 2.3% more than 15 but less than 20 years, 1.2% survey. It was 0.947 at one year, against 0.674 and 0.486
at 5 and 10 years in this survey, respectively.more than 20 but less than 25 years, and 0.2% more than
25 years.
Various data on individual maintenanceThe kidney diseases of the CAPD patients of record
hemodialysis patientsat the end of 1996 were ranked in order as follows:
chronic glomerulonephritis (60.3%), diabetic nephropa- Survey of all patients. The HD session time, Kt/V,
normalized protein catabolic rate (nPCR) and predial-thy (14.5%), nephrosclerosis (3.5%), polycystic kidney
(1.8%), and lupus nephritis (1.3%). ysis plasma creatinine concentration items in the 1996
year-end survey were virtually equivalent to the respec-
Patient death tive surveys in the 1993 and 1994 questionnaires [6] and
therefore, the data are not included here.Causes of death in patients on maintenance extra-
corporeal hemopurification. Based on individual patient Dialyzer membrane materials and membrane area. The
cuprammonium rayon membrane was most frequentlysurvey results, the number of patient deaths can be deter-
mined by cause of death. The causes of death in extracor- used (24.0%), followed by cellulose triacetate membrane
(18.7%), polymethylmethacrylate (PMMA) membraneporeal hemopurification patients during 1996 were as
follows in the order of frequency: heart failure (24.2%), (12.9%), and polysufone (PS) membrane (11.9%). Among
these membranes, cellulose triacetate, PMMA, and PSinfection (14.0%), cerebrovascular disease (13.0%), ma-
lignant tumor (8.0%), and myocardial infarction (7.3%). membranes are all high-flux types in Japan.
The mean length on HD of patients on treatment threeAs indicated in Table 6, heart failure decreased, and
infectious diseases increased as a cause of death during times a week was investigated in terms of the respective
dialyzer membrane materials used. Those using cupram-the five-year period concerned.
Causes of death in CAPD patients. The causes of death monium rayon membranes were found to have a shorter
term (6.1 6 5.6 years) of HD treatment, whereas syn-during 1996 were as follows in the order of frequency:
heart failure (23.4%), infection (19.7%), cerebrovascular thetic membranes [that is, polyacrylonitrile (PAN) mem-
brane (7.6 6 6.4 years), PS membrane (7.7 6 6.4 years)]disease (12.0%), myocardial infarction (10.1%), and
cachexia (7.3%). In comparison with the extracorporeal tended to be used more for those on HD for a longer
term.hemopurification patients, the CAPD patients succumbed
to infectious diseases or cachexia more often. The average membrane area was 1.46 6 0.34 m2. There
was no difference in membrane area among dialyzersAs indicated in Table 7, as a cause of death, heart
failure and cachexia decreased, but myocardial infarction with various membrane materials.
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Table 6. Causes of death in patients on maintenance extracorporeal hemopurification
1992 1993 1994 1995 1996
Cause of death N % N % N % N % N %
Heart failure 3,190 31.2 3,258 30.1 3,279 28.5 3,235 25.5 3,257 24.2
Cerebrovascular disease 1,394 13.7 1,465 13.5 1,626 14.1 1,695 13.3 1,751 13.0
Infection 1,057 10.4 1,234 11.4 1,352 11.8 1,664 13.1 1,881 14.0
Bleeding 272 2.7 304 2.8 339 2.9 361 2.8 363 2.7
Malignant tumor 741 7.3 838 7.7 867 7.5 959 7.5 1,074 8.0
Cahexia 660 6.5 719 6.6 665 5.8 781 6.1 866 6.4
Myocardial infarction 579 5.7 609 5.6 790 6.9 934 7.3 982 7.3
Sudden death 399 3.9 474 4.4 524 4.6 569 4.5 599 4.4
Liver diseases 241 2.4 250 2.3 303 2.6 298 2.3 337 2.5
Dialytic encephalopathy 16 0.2 21 0.2 17 0.1 15 0.1 10 0.1
Suicide 78 0.8 84 0.8 99 0.9 61 0.5 119 0.9
Ileus 101 1.0 111 1.0 106 0.9 125 1.0 129 1.0
Pulmonary embolism 46 0.5 56 0.5 66 0.6 93 0.7 80 0.6
Death by disaster 78 0.8 83 0.8 69 0.6 102 0.8 84 0.6
Others 18 0.2 18 0.2 19 0.2 25 0.2 24 0.2
Miss/unknown 1,342 13.1 1,299 12.0 1,377 12.0 1,792 14.1 1,921 14.3
Total 10,212 100.0 10,823 100.0 11,498 100.0 12,709 100.0 13,477 100.0
N is the number of patients.
Table 7. Causes of death in CAPD patients
1992 1993 1994 1995 1996
Cause of death N % N % N % N % N %
Heart failure 171 29.6 159 26.2 171 24.5 163 24.2 150 23.4
Cerebrovascular disease 73 12.7 84 13.9 95 13.6 103 15.3 77 12.0
Infection 98 17.0 96 15.8 123 17.6 126 18.7 126 19.7
Bleeding 9 1.6 10 1.7 9 1.3 11 1.6 17 2.7
Malignant tumor 18 3.1 13 2.1 24 3.4 12 1.8 22 3.4
Cahexia 63 10.9 66 10.9 55 7.9 52 7.7 47 7.3
Myocardial infarction 44 7.6 48 7.9 77 11.0 64 9.5 65 10.1
Sudden death 21 3.6 25 4.1 38 5.4 33 4.9 27 4.2
Liver diseases 0 0.0 13 2.1 10 1.4 5 0.7 8 1.2
Dialytic encephalopathy 0 0.0 1 0.2 1 0.1 1 0.1 1 0.2
Suicide 3 0.5 3 0.5 5 0.7 3 0.4 3 0.5
Ileus 4 0.7 4 0.7 8 1.1 3 0.4 4 0.6
Pulmonary embolism 0 0.0 5 0.8 4 0.6 3 0.4 7 1.1
Accident or disaster 1 0.2 4 0.7 2 0.3 5 0.7 3 0.5
Others 4 0.7 4 0.7 2 0.3 2 0.3 2 0.3
Miss/unknown 68 11.8 71 11.7 75 10.7 87 12.9 82 12.8
Total 577 100.0 606 100.0 699 100.0 673 100.0 641 100.0
N is the number of patients.
Surgical release of carpal tunnel. The relationship be- those on CAPD, an analysis of covariance was conducted
taking the pretreatment plasma b2-microglobulin (b2m)tween the length on HD and the past history of surgical
release of carpal tunnel was investigated. As seen in concentration as a dependent variable, and sex, age,
length on RRT, presence or absence of diabetes, andTable 8, the number of patients who had the past history
of surgical release of carpal tunnel in either or both treatment modality were independent variables. The
thus-obtained least square mean was compared amongwrists rose sharply in those on HD for more than 15
years, nearly 30% in those on HD for over 15 but less the patient groups on HD, HDF, HF, and CAPD.
The least square mean of pretreatment plasma b2mthan 20 years, nearly 50% in those on the therapy for
over 20 but less than 25 years, and nearly 70% in those concentration was lowest in the HF patients (27.1 6 1.1
mg/liter, N 5 81), followed by HDF patients (29.6 6 0.3on HD for over 25 years.
Predialysis b2-microglobulin concentration: (1) Plasma mg/liter, N 5 3,089) and CAPD patients (31.3 6 0.3 mg/
liter, N 5 2,785). The concentration in HD patients wasb2-microglobulin concentration and treatment modality.
For patients on HD, HDF, or HF three times a week or found to be 31.6 6 0.2 mg/liter (N 5 78,593).
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Table 8. Distribution of hemodialysis patients by history of surgical release of carpal tunnel and years on renal replacement therapy
Surgical release of carpal tunnel
Yes
Years on dialysis No One arm Both arms Subtotal Missing value Grand total
0| 35,911 (99.9) 41 (0.1) 3 (0.0) 35,955 (100.0) 6,258 42,213
2| 25,037 (99.5) 103 (0.4) 18 (0.1) 25,158 (100.0) 14,190 39,348
5| 21,723 (98.8) 189 (0.9) 71 (0.3) 21,983 (100.0) 12,458 34,441
10| 10,809 (91.4) 666 (5.6) 355 (3.0) 11,830 (100.0) 6,474 18,304
15| 5,169 (72.4) 1,074 (15.0) 897 (12.6) 7,140 (100.0) 3,572 10,712
20| 1,667 (50.1) 731 (22.0) 932 (28.0) 3,330 (100.0) 1,421 4,751
25| 83 (32.2) 62 (24.0) 113 (43.8) 258 (100.0) 114 372
Total 100,399 (95.0) 2,866 (2.7) 2,389 (2.3) 105,654 (100.0) 44,487 150,141
Numbers in parentheses indicate the percentage of patients with or without the past history of surgical release of carpal tunnel.
No indicates patients without a past history of surgical release of carpal tunnel;
Yes indicates patients with a past history of surgical release of carpal tunnel;
Missing value comprises patients without data on their past history of surgical release of carpal tunnel.
(2) Plasma b2-microglobulin concentration and patient ysis plasma b2m concentrations relative to the predialysis
concentration as the b2m reduction rate (not correctedage. For patients on HD three times a week, an analysis
of covariance was conducted taking the pretreatment by the reduction of extracellular fluid volume during
treatment), we investigated the relationship between thisplasma b2m concentration as a dependent variable and
sex, age, length on HD, presence/absence of diabetes, reduction rate and various parameters.
b2-Microglobulin reduction rate and treatment modality.Kt/V, HD session duration, b2m reduction rate, dialyzer
membrane material, and dialyzer membrane area as in- For patients on HD, HDF, or HF three times a week,
an analysis of covariance was conducted taking the pre-dependent variables. The thus-obtained least square
mean of plasma b2m concentration was 35.7 6 5.0 mg/ treatment plasma b2m reduction rate as a dependent
variable and sex, age, length on RRT, presence or ab-liter (N 5 3) in patients under 15 years of age, 32.1 6
0.9 mg/liter (N 5 186) at over 15 but under 30 years, sence of diabetes, Kt/V, treatment session duration, dia-
lyzer membrane material, dialyzer membrane area, and33.1 6 0.7 mg/liter (N 5 1,085) at over 30 but under 45
years, 32.3 6 0.6 mg/liter (N 5 3,383) in those over 45 treatment modality as independent variables. The least
square means of the b2m reduction rates by HF (30.5 6but under 60 years, 31.8 6 0.6 mg/liter (N 5 3,223) in
those over 60 but under 75 years, 30.2 6 0.7 mg/liter (N 5 2.8%, N 5 29) and HDF (35.0 6 1.6%, N 5 471) were
higher than that by HD (28.7 6 1.5%, N 5 8,688), respec-798) at over 75 but under 90 years, and 28.5 6 2.8 mg/
liter (N 5 10) in patients over 90 years of age. Thus, the tively.
b2-Microglobulin reduction rate and dialyzer membraneover-75 age group exhibited a slightly lower predialysis
plasma b2m concentration. material. For patients on HD three times a week, an
analysis of covariance was conducted taking the pretreat-(3) Plasma b2-microglobulin concentration and dura-
tion on hemodialysis. By the same analysis, it was found ment plasma b2m reduction rate as a dependent variable
and sex, age, length of time on RRT, presence or absencethat the least square mean of plasma b2m concentration
was 27.9 6 1.0 mg/liter (N 5 1,577) for patients on HD of diabetes, presence or absence of a past history of surgi-
cal release of carpal tunnel, Kt/V, HD session duration,for two years or less, 31.8 6 1.0 mg/liter (N 5 2,248) for
those on HD over two but less than five years, 33.9 6 dialyzer membrane material, and dialyzer membrane
area as independent variables. The least square mean of1.0 mg/liter (N 5 2,288) at over 5 but under 10 years,
34.6 6 1.0 mg/liter (N 5 1,275) at over 10 but less than the b2m reduction rate of patients using the PS mem-
brane was far superior at 56.1 6 1.5% (Table 9), followed15 years, 33.5 6 1.0 mg/liter (N 5 815) at more than 15
but less than 20 years, 30.4 6 1.1 mg/liter (N 5 411) at by the polyamide membrane at 47.4 6 2.1%. The other
high-flux membranes [that is, polyethersulfone polyary-over 20 but less than 25 years, and 31.6 6 1.4 mg/liter
(N 5 74) for those on HD more than 25 years. Thus, the late blend polymer (PEPA), PAN, PMMA, and cellulose
triacetate membranes] also showed high values: PEPA,plasma b2m concentration was highest among patients on
HD from 10 to 15 years. In patients whose length on 40.9 6 1.7%; PMMA, 33.8 6 1.5%; PAN, 33.4 6 1.7%;
and cellulose triacetate, 30.4 6 1.5%. The cuprammon-HD was either more or less than that, the plasma b2m
concentration tended to decrease as the length on HD ium rayon membrane showed a low least square mean
of the b2m reduction rate at 17.2 6 1.5%.was either longer or shorter.
b2-Microglobulin reduction rate. Taking the percent- b2-Microglobulin reduction rate and dialyzer membrane
area. The results of the same analysis indicated that theage of the difference between the predialysis and postdial-
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nPCR g/kg/day N mean seMembrane material N mean se
EVAL 284 16.88 6 1.68 ,0.5 22 5.43 6 0.39
0.5| 586 6.40 6 0.19PA 73 47.44 6 2.12
PAN 283 33.36 6 1.68 0.7| 2,453 6.79 6 0.18
0.9| 2,767 6.82 6 0.18PEPA 297 40.90 6 1.66
PMMA 1469 33.78 6 1.54 1.1| 1,151 7.02 6 0.19
1.3| 235 7.03 6 0.21PS 1677 56.11 6 1.52
Cupraammonium rayon 736 17.36 6 1.57 1.5| 37 7.18 6 0.31
1.7| 9 7.74 6 0.56PEG grafted cellulose 137 20.25 6 1.87
Hemophan 35 22.91 6 2.64 Abbreviations are: nPCR: normalized protein catabolic rate; l.s. mean, least
Cellulos diacetate 307 26.27 6 1.67 square mean; se, standard error.
Cellulos triacetate 1552 30.37 6 1.51
Saponified cellulose ester 106 18.67 6 1.96
Surface modified membrane with vitamin E 78 16.18 6 2.09
Others 8 28.64 6 4.79
patients who had been on HD for more than two years,Abbreviations are: EVAL, ethylene vinyl alcohol; PA, polymide; PAN, poly-
acrylonitrile; PEPA, polythersulfone polyarylate blend polymer; PMMA, poly- those who had been on HD for less than two full years
methylmethacrylate; PS, polysulfone; N, number of patients; l.s. mean, least
were eliminated from the cohort.square mean; se, standard error.
The results of the analysis indicated that the least
square mean of the HbA1c level was higher at 6.97 6
0.20% (N 5 2,713) in female HD patients with diabetes
least square mean of the b2m reduction rate was 19.7 6 than that in male HD patients with diabetes at 6.63 6
2.1% (N 5 76) when the membrane area was 0.8 m2 or 0.20% (N 5 4,547).
less, 19.9 6 1.8% (N 5 191) with a membrane area of HbA1c level and patient age. By the previously men-
0.8 to 1.0 m2, 26.4 6 1.6% (N 5 754) with a membrane tioned analysis, in patients over 15 but less than 30 years
area of 1.0 to 1.2 m2, 29.1 6 1.6% (N 5 1297) with a of age, the thus-obtained least square mean of HbA1c
membrane area of 1.2 to 1.4 m2, 30.0 6 1.6% (N 5 1,666) level was 8.00 6 0.48% (N 5 12), against 7.49 6 0.17%
with a membrane area of 1.4 to 1.6 m2, 33.5 6 1.6% (N 5 (N 5 409) in patients over 30 but under 45 years, 7.03 6
1,463) with a membrane area of 1.6 to 1.8 m2, 36.1 6 0.15% (N 5 2,463) in those over 45 but under 60 years,
1.6% (N 5 987) with a membrane area of 1.8 to 2.0 m2, 6.67 6 0.15% (N 5 3,702) in those over 60 but under
39.1 6 1.6% (N 5 608) with a membrane area of more 75 years, and 6.49 6 0.16% (N 5 668) at over 75 but
than 2.0 m2. Thus, there was a definite tendency for the under 90 years of age. Thus, the older the patient, the
b2m reduction rate to increase as the membrane area lower the HbA1c level tended to be. There were no
was larger. patients 15 years of age or less and a few patients 90
years of age or over.
Glycohemoglobin A1c (HbA1c) level HbA1c level and nPCR. As shown in Table 10, the
HbA1c level and treatment modality. For diabetics on results of the previously mentioned analysis indicated
HD three times a week or those on CAPD, an analysis that the higher the nPCR value calculated on the basis
of covariance was conducted taking HbA1c level as a of predialysis and postdialysis plasma urea nitrogen con-
dependent variable and sex, age, length on RRT, and centrations [7], the higher also was the HbA1c level.
treatment modality as independent variables. The ana-
Survey of additional items by floppy diskettelytic results indicated that there was no significant differ-
ence in the thus-obtained least square mean of HbA1c Approximately 681 facilities wanted to use the floppy
level between HD, 6.82 6 0.15% (N 5 9,958), and CAPD, diskette for the survey. Thus, 51,276 patients in these
6.95 6 0.19% (N 5 204), patients. facilities were surveyed using the floppy diskette, and
HbA1c level and sex differences. For those with diabe- data on additional items (that is, dose of recombinant
tes who were on HD three times a week, an analysis human erythropoietin administered, cardiothoracic ra-
of covariance was conducted taking HbA1c level as a tio, and systolic and diastolic blood pressure) were ob-
dependent variable and sex, age, length on RRT, and tained from the facilities.
nPCR as independent variables. Here, although nPCR Dose of recombinant human erythropoietin (rHuEPO).
may be underestimated when residual renal urea clear- In this survey, a range of the rHuEPO dosages adminis-
ance is ignored, the Patient Registration Committee did tered was investigated instead of the actual rHuEPO
not have any data on residual renal function. Thus, as- dose itself. For the investigation, the following seven
ranges were used: none, less than 1,499 units, 1,500 unitssuming that a residual renal function can be ignored in
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Table 11. Distribution of patients in terms of treatment modality and recombinant human erythropoietin (rHuEPO) dose
Hemodialysis Hemodiafiltration CAPD
rHuEPO dose
Units/week N % N % N %
Not used 7,971 23.8 431 35.1 754 40.7
1 | 1499 1,139 3.4 53 4.3 63 3.4
1500 | 2999 4,102 12.2 116 9.4 229 12.4
3000 | 4499 6,639 19.8 195 15.9 252 13.6
4500 | 5999 6,058 18.1 187 15.2 184 9.9
6000 | 8999 4,069 12.1 135 11.0 300 16.2
9000 | 3,526 10.5 106 8.6 71 3.8
rHuEOP with anabolic steroid 19 0.1 5 0.4 1 0.1
Total 33,523 100.0 1,228 100.0 1,854 100.0
N is the number of patients.
Table 12. Distribution of hemodialysis patients in terms of years on renal replacement therapy and rHuEPO dose
Years on renal replacement therapy
0| 5| 10| 15| 20| 25 Total
rHuEPO dose
Units/week N % N % N % N % N % N % N %
Not used 3,140 19.1 1,852 22.1 1,363 29.6 1,044 38.4 525 42.1 47 38.2 7,971 23.8
1 | 1499 604 3.7 253 3.0 151 3.3 83 3.1 43 3.4 5 4.1 1,139 3.4
1500 | 2999 2,020 12.3 1,066 12.7 562 12.2 310 11.4 127 10.2 17 13.8 4,102 12.2
3000 | 4499 3,377 20.5 1,699 20.3 877 19.0 471 17.3 195 15.6 20 16.3 6,639 19.8
4500 | 5999 3,165 19.2 1,589 19.0 739 16.0 377 13.9 173 13.9 15 12.2 6,058 18.1
6000 | 8999 2,240 13.6 1,016 12.1 483 10.5 222 8.2 99 7.9 9 7.3 4,069 12.1
9000 | 1,901 11.6 888 10.6 428 9.3 213 7.8 86 6.9 10 8.1 3,526 10.5
rHuEPO with anabolic steroid 8 0.0 5 0.1 5 0.1 1 0.0 0 0.0 0 0.0 19 0.1
Total 16,455 100.0 8,368 100.0 4,608 100.0 2,721 100.0 1,248 100.0 123 100.0 33,523 100.0
N is the number of patients.
to less than 2,999 units, 3,000 units to less than 4,499 absence of diabetes, and treatment modality as indepen-
dent variables. Second, the same analysis was performedunits, 4,500 units to less than 5,999 units, 6,000 units to
less than 8,999 units, and over 9,000 units per week. For taking CTR (that is, postdialysis CTR in case of HD
patients) as a dependent variable and sex, age, lengththis reason, we could not calculate the mean rHuEPO
dose or perform a multivariate analysis. on RRT, presence or absence of diabetes, and treatment
modality as independent variables.Table 11 brings together the relationships of rHuEPO
dose administered and treatment modalities (HD, HDF The analytic results indicated that the least square
mean of CTR in CAPD patients was smaller at 50.6 6and CAPD). The proportion of the patients not receiving
rHuEPO was larger in the order of CAPD, HDF, and 0.3% (N 5 1,348) than the least square mean of predial-
ysis CTR at 51.1 6 0.3% (N 5 21,117), but that in CAPDHD. Also, the rHuEPO doses given tended to increase
in the order of CAPD, HDF, and HD. patients was slightly greater at 50.4 6 0.3% (N 5 1,348)
than the least square mean of postdialysis CTR at 49.3 6With patients given HD three times a week, data were
compiled on the relationship between the rHuEPO dose 0.3% (N 5 9,706).
(2) CTR and sex differences. For patients on HD threeadministered and length of time on HD. As shown in
Table 12, the longer the duration of HD, the greater the times a week, an analysis of covariance was conducted
taking predialysis CTR as a dependent variable and sex,proportion of patients who did not receive rHuEPO.
Cardiothoracic ratio (CTR). The mean CTR was age, length on RRT, and presence or absence of diabetes
as independent variables. The analytical results indicated50.46 6 5.37% (N 5 21,134) in HD patients three times
a week before the first HD session of the week and that females had a slightly greater least square mean of
CTR at 51.9 6 0.7% (N 5 8,110) than males at 49.4 649.40 6 5.60% (N 5 1,353) after the session.
(1) CTR of HD and CAPD patients. First, for patients 0.7% (N 5 13,007).
(3) CTR and patient age. By the same analysis, it wason HD three times a week and those on CAPD, an
analysis of covariance was conducted taking CTR (that indicated that the higher the age, the greater the least
square means of CTR was found to be: 47.5 6 0.3%is, predialysis CTR in case of HD patients) as a depen-
dent variable, and sex, age, length on RRT, presence or (N 5 462) at over 15 but under 30 years, 48.4 6 0.1%
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(N 5 2,622) at over 30 but under 45 years, 50.0 6 0.1% DISCUSSION
(N 5 8,234) at over 45 but under 60 years, 51.6 6 Survey results on current status of dialysis facilities
0.1% (N 5 7,670) at over 60 but under 75 years, 53.8
Rough totals. The Patient Registration Committee of
6 0.1% (N 5 2,098) at over 75 but under 90 years, and the Japanese Society for Dialysis Therapy has divided
56.0 6 0.9% (N 5 30) in patients over 90 years of age. the country into 62 areas, requesting a dialysis expert in
Blood pressures and treatment modality. (1) Systolic each of these areas to serve as the coordinators of the
and diastolic blood pressures. For patients on HD, HDF, statistical survey. These appointed coordinators are in
or HF three times a week or those on CAPD, an analysis contact not only with existing dialysis facilities in their
of covariance was conducted taking the systolic or dia- respective areas, but they also reach out to the new
stolic pressure as a dependent variable and sex, age, dialysis facilities to request their ongoing cooperation.
length on RRT, presence or absence of diabetes, and Thus, it is considered that the committee members are
treatment modality as independent variables. The results in contact with more than 99% of the dialysis facilities
indicated that the least square means of predialysis sys- nationwide. Thus, the institutions covered by this ques-
tolic and diastolic pressures in HD patients were 145.4 6 tionnaire survey represent nearly all of those providing
0.9 mm Hg (N 5 32,546) and 74.7 6 0.5 mm Hg (N 5 such services. In the five-year period leading up to 1996,
32,344), respectively, against 142.9 6 1.1 mm Hg (N 5 over 99% of the facilities responded to the questionnaire
1,172) and 73.6 6 0.6 mm Hg (N 5 1,165) in HDF every year. Therefore, virtually every patient receiving
patients. The corresponding mean values were 135.2 6 renal replacement treatment in Japan is considered to
1.1 mm Hg (N 5 1,510) and 74.6 6 0.6 mm Hg (N 5 have been surveyed in this manner.
1,498) in CAPD patients. Thus, the least square means On the basis of this study, the population of the pa-
of predialysis systolic and diastolic pressures were sig- tients receiving RRT in 1996 was 167,192 persons, or
nificantly lower in CAPD patients than in HD or HDF 1,328 persons per million general population. The figures
patients. in 1986 indicated a population of patients receiving RRT
(2) Blood pressure and sex differences. For patients in Japan of 73,537 or 604 persons per million general
on HD three times a week, an analysis of covariance population [8]. This indicates the population of the RRT
was conducted taking the systolic or diastolic pressure patient grew more than twofold in that decade. This
as a dependent variable and sex, age, duration on RRT, survey’s results indicated that the high prevalence of
and presence or absence of diabetes as independent vari- patients on maintenance RRT was due to the prevalence
ables. The results indicated that the least square means of patients on maintenance HD treatment. On the basis
of predialysis systolic and diastolic pressures were 147.2 6 of this study, 91.6% of the patients on maintenance RRT
1.4 mm Hg (N 5 19,400) and 75.9 6 0.8 mm Hg (N 5 were on maintenance HD.
19,314) in males, against the slightly lower 145.1 6 1.4 Also, the mean age of such patients was 58.6 years in
mm Hg (N 5 13,146) and 74.8 6 0.8 mm Hg (N 5 1996, against 51.1 years 10 years earlier [8], reflecting the
13,030) in female patients. Thus, there was no significant rapid aging of such patients in Japan. In the 1996 survey,
difference in the systolic or diastolic pressure between diabetic patients accounted for 21.6% of the population
males and females. of patients receiving RRT, versus only 10.5% in 1986
(3) Blood pressure and patient age. By the same analy- [8]. Thus, the ratio of diabetic patients among the popula-
sis, the systolic and diastolic pressures were found to be tion of patients receiving such treatment nearly doubled
127.6 6 8.9 mm Hg (N 5 7) and 70.6 6 5.1 mm Hg (N 5 in a decade in Japan, but it was still lower than the rate
7) in patients 15 years or under, 146.1 6 1.0 mm Hg (N 5 in the United States (35.1% at the end of 1995) [2].
639) and 79.8 6 0.6 mm Hg (N 5 635) at over 15 but Survival rate. The results compiled on survival rates
under 30 years, 149.3 6 0.5 mm Hg (N 5 3,816) and for this year were virtually the same as for 1994 [6], so
82.0 6 0.3 mm Hg (N 5 3,791) at over 30 but under 45 they are not discussed here.
years, 151.2 6 0.4 mm Hg (N 5 12,439) and 79.9 6 0.2
Various data on individual maintenancemm Hg (N 5 12,359) at over 45 but under 60 years,
hemodialysis patients150.4 6 0.4 mm Hg (N 5 12,178) and 75.6 6 0.2 mm
Hg (N 5 12,116) at over 60 but under 75 years, 148.1 6 Dialyzer membrane materials and membrane area.
0.5 mm Hg (N 5 3,425) and 71.2 6 0.3 mm Hg (N 5 Cellulose membranes (for example, cuprammonium
3,394) at over 75 but under 90 years, and 150.5 6 3.7 rayon membrane, cellulose diacetate membrane, triace-
mm Hg (N 5 42) and 68.5 6 2.1 mm Hg (N 5 42) in tate membrane) were used most often; 64% of the pa-
those over 90 years of age. Thus, both the systolic and tients used them, possibly because of their relatively
diastolic pressures were highest among the 45- to 59- lower price. Approximately 36% of the patients used
year-old patients and those under 15 years of age who synthetic membranes (such as the PMMA membrane,
PS membrane, and PAN membrane). Because no resultsserved as the controls.
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are available from other countries on numerous HD The reason for the lower plasma b2m concentration
in patients with an HD treatment duration of less thanpatients in terms of membrane materials or membrane
areas of the dialyzers they employed, a comparison could two years is probably the residual renal function, as it
is one of the main factors related to plasma b2m concen-not be made between the Japanese data and those of
other nations. tration. Unfortunately, the Patient Registration Commit-
tee of the Japanese Society for Dialysis Therapy did notAs made clear by this survey with regards to patients
with a prior history of surgical release of carpal tunnel, have any data on residual renal function.
b2-Microglobulin reduction rate. The analysis of co-the longer the duration on HD therapy, the more compli-
cations of dialysis-related b2m-amyloidosis appeared [9]. variance in terms of the dialyzer membrane materials
showed that the b2m reduction rate was highest in pa-This may be the reason for the greater employment of
synthetic membranes for those on a longer duration of tients with whom a PS membrane was used, followed by
those with whom a polyamide, PEPA, or PAN mem-HD in Japan.
Surgical release of carpal tunnel. The carpal tunnel brane was used. The especially high b2m reduction rate
in patients with whom a PS membrane was used wassyndrome afflicts patients on long-term RRT [10]. This
survey made it clear that there is a rapidly growing pro- not due to the increased permeability of low molecular
weight protein through reuses of the dialyzer [11, 12]portion of patients who have undergone surgical release
of carpal tunnel at over 15 years of HD treatment. because in Japan, reuse of a dialyzer is not permitted.
Glycohemoglobin A1c level. In comparison of thePredialysis plasma b2-microglobulin concentration.
This survey results showed that the predialysis plasma HbA1c levels in HD and CAPD patients, both in whom
diabetes was the disease causing renal failure, there wasb2m concentration was lowest in HF and HDF, followed
by higher levels in CAPD and HD. Although not covered no significant difference in HbA1c level between CAPD
and HD patients, in spite of the fact that glucose is addedin this survey, much of the replacement fluid may be
used in both HF and HDF, but there is little convection to the dialysate used for CAPD at a high concentration.
In these data, there was a clear tendency for thein CAPD and HD, so the above-mentioned results pre-
sumably reflect the differences in the replacement fluid HbA1c level to be higher when the nPCR was higher.
These suggests that when there is a high dietary energyvolume.
As for the relation between age and the predialysis intake, the HbA1c level becomes higher, as there is a
linear correlation between the daily dietary protein in-plasma b2m concentration, the least square mean of pre-
dialysis plasma b2m concentration that had been adjusted take (x; g/kg), which is considered to be reflected by the
nPCR, and daily dietary energy intake (y; kcal/kg): y 5by related factors was highest in patients ages 30 to 45
years and declined slightly after the age of 45. Among 16.9x 1 587; r 2 5 0.665; N 5 79 (unpublished data).
In considering the relationship between age and thethe factors used for the adjustment, the b2m reduction
rate was included. Therefore, the lower b2m concentra- HbA1c level, the younger the patient, the higher the
HbA1c tended to be, and the older the patient, the lowertions in older patients cannot be attributed to a larger
b2m reduction rate. the tendency for it to be found. Because nPCR was
included among the factors used for the adjustment,The predialysis plasma b2m concentration obtained by
an analysis of covariance was found to be highest among some reason other than diminished energy intake during
the aging process may explain why HbA1c decreasespatients on HD from 10 to 15 years. The concentration
tended to be lower with patients on HD either for a with age.
In this survey, the HbA1c level was higher in femaleslonger or shorter time.
In this analysis, influences of sex difference, different than in males for unknown reasons. Again, because the
least square mean of the HbA1c level was adjusted byage distribution, different percentages of diabetes pa-
tients, different Kt/V distribution, different distribution nPCR, it may be difficult to ascribe the difference in
HbA1c values between the sexes to a difference in di-of material and area of dialyzer membrane used, and
b2m reduction rate were mathematically adjusted when etary energy intake.
plasma b2m level was compared among patients with
Additional survey items for facilities desiring floppydifferent length on HD. Thus, the reasons for the differ-
diskette surveyences in predialysis plasma b2m concentrations among
patients with different lengths on HD may be other than Dose of recombinant human erythropoietin adminis-
tered. This survey made it clear that the longer the lengththese factors.
As shown by compilation of data on HD treatment on HD, the less rHuEPO was needed. It has been re-
ported that as the length on HD increases, more cystsduration and the plasma b2m concentration, when the
length on HD was less than two years, the plasma b2m develop in the residual kidneys of the HD patient, and
anemia tends to improve [13]. This report coincides withconcentration tended to be lower, probably due to resid-
ual renal function. this survey’s results.
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tration; IPD, intermittent peritoneal dialysis; nPCR, normalizedCardiothoracic ratio and blood pressure. The CTR in
protein catabolic rate; PEPA, polyethersulfon polyarylate blend poly-
CAPD patients was found to be smaller than the predial- mer; PMMA, polymethylmethacrylate; PS, polysufone; rHuEPO, re-
combinant human erythropoietin; RRT, renal replacement therapy.ysis CTR in HD patients, but slightly greater than the
postdialysis mean CTR. This might be because the HD
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